Pfizer has reported a four-fold increase in the success rate of its new molecular entity clinical trials over the past five years. From 2016 to 2020, 21 percent of its trials met their endpoints, up from just 5 percent in 2015 and well above the 8 percent industry average through 2019.

The company also reported a five-year average success rate of 85 percent for phase 3 trials through 2020, up from 70 percent in 2015 and above the industry mark of 72 percent through 2019.

Phase 2 trials achieved a 52 percent success rate through 2020, up from 15 percent in 2015. By comparison, the industry’s average for phase 2 success through 2019 was 29 percent. Pfizer’s three-year average success rate for its phase 1 trials was 48 percent through 2020, unchanged from 2015 yet still above the industry average of 40 percent through 2019.

Read Pfizer’s report here: https://bit.ly/2MVFMcM.